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If You Build It, Will They Come?
In a now-classic scenario, jobs leave
a company town when the company
folds. But some relatively small urban
centers, like Kalamazoo and Pitts-
burgh, are building biotech incuba-
tors in a bid to save their economies
in the wake of industrial upheaval.
They are modeled on biotech cen-
ters such as Boston, South San
Francisco, San Diego, and New York,
which are blessed with a strong in-
novation environment, capital net-
works, and a pool of experienced
managers. Following distinctively re-
gional efforts, Kalamazoo and Pitts-
burgh are at different stages in their
economic evolutions.
Although each early-stage biotech
company creates only a small num-
ber of jobs directly, the type of jobs
created and the highly skilled pro-
fessionals these companies may
attract, as well as their multiplier ef-
fects, make biotech the choice of
regional developers. The challenge
these cities face is how to build
enough critical mass that will sus-
tain a biotech industry over the
long term.
Stick Around Kalamazoo
By the time Pfizer bought out Phar-
macia (formerly Upjohn), Kalama-
zoo’s biggest employer at 6,500
people, in a $60 billion dollar deal in
2002 and gutted its Kalamazoo
R&D operations, Michigan had al-
ready lost 200,000 jobs, mainly in
the manufacturing sector. That left
the area not only with fewer employ-
ment opportunities but also con-
fronting the threat of losing some of
its most skilled and educated scien-
tists and engineers, a population
essential to attract high profit mar-
gin industries.
In a contingency plan set up in
1998, a consortium of public and
private businesses and academics
had formed a development agency,
“Southwest Michigan First” (SMF),
focused on the life sciences. $13 mil-
lion was committed to build a 58,000
square-foot wet laboratory, dubbed
the Southwest Michigan Innovation
Center (http://www.kazoosmic.com/).
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shen Pfizer announced the bad
ews, SMF launched an ad cam-
aign called “Stick Around.” With a
10 million state pharmaceutical
&D credit and equipment donated
y Pfizer, the fund seeded some
tartups and recruited about 200
cientists and other skilled workers
rom the departing drug company.
ine new research and technology
irms were created in the process.
urrently, the Southwest Michigan
nnovation Center has 15 start-up
enants. One of the most successful
s Kalexsyn which was started by
wo former Upjohn chemists and
erforms contract medical chemis-
ry work.
i
M
c
c
t
n
t
l
t
v
l
p
l
t
g
“
cSome relatively small
rban centers, like Kala-
azoo and Pittsburgh,
re building biotech incu-
ators in a bid to save
heir economies in the
ake of industrial up-
eaval.”
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bDouglas R. Morton, Jr., CEO of
he Southwest Michigan Innovation
enter is a chemist and former
fizer vice president. “Kalamazoo
as a pretty rich heritage in health
are and life science,” Morton says,
iting firms like the medical device
ompany Stryker and service pro-
iders Aftec and MPI Research. Al-
hough Michigan has a distinct ad-
antage of low costs in living and
usiness, the historic lack of ven-
ure fund money remains a barrier.
igh stakes individual investors,
nown as angels, are new to the re-
ional biotech scene as well.
“The angel community does not
ave the length of time and experi-
nce in investing in life sciences
ompanies. They are unfamiliar with
he high-risk/high-reward nature of
nvesting in life sciences to the
ame degree that an angel residing
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hn Boston or South San Francisco,”
orton says. Valuations are another
hallenge for companies outside of
oastal areas where valuations tend
o run higher for the same tech-
ology.
Morton said that another issue is
hat although Kalamazoo doesn’t
ack people with technical skills,
hey need to concentrate on de-
eloping a core of entrepreneurial
eaders. It is difficult to recruit more
eople with the right skills because
ife science is a high-risk proposi-
ion and no alternative exists in the
eographic area if a company fails.
The challenge for us is to build a
ritical mass and density of oppor-
unities that will encourage people
o stay and relocate to the area,”
ays Morton.
Despite these problems and Kala-
azoo’s small size, the city boasts
ealth and connections. Local ven-
ure funds Apjohn Ventures and
Gap Ventures are supplemented
y the $50 million Southwest Michi-
an Life Science Fund, oriented as
local economic development fund
ather than one aimed strictly at
roviding return on investment as
ell as a venture fund of funds run
y the state of Michigan. “The Life
cience Fund has already gotten a
ot of notoriety. We’ve had people
rite in from the coasts asking if
hey can join up. We say, ‘Sure, if
ou can relocate!’” says Morton.
Viable ideas are the lifeblood of
ny incubator. Morton’s team scans
he area universities and also seeks
echnologies outside of Michigan.
By fourth quarter, our facility will
e completely full. In our view, that
s a measure of some degree of
uccess. Now the challenge is to
lesh out the pipeline,” Morton says.
ittsburgh
ittsburgh, formerly known as a steel
own, is in the process of trans-
orming itself into a biomedical cen-
er. Former Governor Tom Ridge
ommitted $33 million to build the
ittsburgh Life Sciences Green-
ouse, a public/private economic
Chemistry & Biology
952partnership comprising the Univer-
sity of Pittsburgh, Carnegie Mellon
University, and the Commonwealth
of Pennsylvania along with private
funds.
Like Michigan, Pittsburgh was
also facing hard times. “The ma-
jor employers had tanked,” says
Margaret McDonald, Assistant Vice
Chancellor for Academic Affairs at
the University of Pittsburgh, Health
Sciences. “The Greenhouse was the
result of various task forces over a
number of years. The universities
were a potent force behind this ini-
tiative.”
Pittsburgh has a few advantages
over Kalamazoo. It has a strong
base of universities with long tra-
ditions of biochemistry and chemi-
cal engineering and so harbors an
intrinsic mass of scientists. Pitts-
burgh also is geographically and
culturally closer to the East Coast
and its venture capital and entre-
preneurial culture. The steel indus-
try left Pittsburgh decades ago, so
the city has experience in shifting
its economic base from one indus-
try to another. Michigan’s wounds
are still fresh.
“The good thing about Pittsburgh
is that the city is still contained
enough so that all of the right peo-
ple know each other,” says McDon-
ald. As in Michigan, Pittsburgh also
has a lack of venture capital. “In the
dearth of that, ironically our health
system, the University of Pittsburgh
Medical Center, a large regional
network, is making lots of money,”
says McDonald. “It is reinvesting
that money both in biomedical re-
search at the university level and in
its own investment arm, the UPMC
Strategic Business Initiative.”
“Biotech needs four conditions
to survive: money, connections, IP
[intellectual property], and manage-
ment,” says D. Lansing Taylor, co-
founder of biotech companies Cel-
lumen, Cellomics, and Biological
Detection Systems and currently a
board member of the Greenhouse.
Cellumen was established last year
and recently received funding from
a venture firm, PA Early Stage Part-
ners. Taylor pointed out that Pitts-
burgh is a more affordable place to
do business. In a place like Boston,
companies compete for the same
people, driving up the salaries and
cost of operations. “I’ve started at
least three companies here be-
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pause I believe in Pittsburgh; I con-
ider the universities, R&D, and re-
ional commitment outstanding, but
ringing in good management is a
hallenge. With the right opportu-
ity, people come. Capital is tougher
s venture capitalists like to be
lose to their investments. Twenty
ears ago, San Diego was not the
ot spot for biotechnology; they
orked hard to attract it,” Taylor
ays.
iotech, Not Zeppelins
om Petzinger, cofounder of Launch-
yte, a for-profit Pittsburgh biotech
ncubator now located in the Green-
ouse, is a former business writer
or the Wall Street Journal. Four
ears ago, he and colleagues started
aunchcyte with ten people and
edicated facilities.
“The incubator’s primary objec-
ive is creating value for private in-
estors,” says Petzinger. “If in doing
o, we serve a regional economic
evelopment objective, that is great.
ut the latter is not the principal ob-
ective. An opposite scenario could
ork so long as the secondary ob-
ective [i.e., creating value for the in-
estors] is treated with respect.
here is no point in wasting com-
on resources on businesses that
ave no viability.”
“In the early stage of develop-
ent, the technologies that are be-
ng commercialized are premature,
nd the risks are high,” Petzinger
ays. “That has been the case in ev-
rything we have done. It is not
asy to find an investor to shoulder
he burden of technology risks as
nvestors would rather shoulder the
urden of market risk and competi-
ive risk. This is where organizations
ike the Greenhouse or the Michigan
nitiative can really fill an important
ap.”
According to Petzinger, the busi-
ess model for a biotech startup
hould be focused on accumulating
ntellectual property and then har-
esting value in an exit, either by li-
ensing intellectual property or sell-
ng it to a pharmaceutical company,
hich would then undertake the
ore expensive clinical trials and
DA approvals. It is far less likely
o build a biotech business model
ased on revenue.
To date, none of the original com-
anies formed at Launchcyte havefolded, but the business model has
changed. “We ceased being an in-
cubator,” says Petzinger. Launch-
cyte’s staff has shrunk to Petzinger
and an office manager. “I learned
that what is most important is se-
lecting technologies appropriately,
putting in the right teams, and send-
ing them to market.” At the end
of 2003, Launchcyte received a $1
million cash infusion from the Uni-
versity of Pittsburgh, University of
Pittsburgh Medical Center, and pri-
vate investors. Launchcyte is essen-
tially functioning now as a parallel
entrepreneur in pursuit of multiple
opportunities simultaneously. It is
more a venture capital fund “but
heavy on the venture and light on
the capital,” Petzinger quips. Launch-
cyte has invested around $12 mil-
lion dollars in its original five com-
panies; currently a sixth one is
being formed. “Every one of the
companies drives its market,” Pet-
zinger says. “Three of them have
revenues, real money from the mar-
ketplace. That is the best source of
financing in the world.”
Petzinger remembers that when
he was working in Allentown, Penn-
sylvania and the steel mills went
away, local officials considered cre-
ating jobs by luring in, among other
industries, a dirigible factory. “Zep-
pelins, like the Hindenburg,” Pet-
zinger recalls. “This is better.”
Wendy Wolfson (wendywolfson@nasw.org)
is a science and technology writer based in
Oakland, CA.
